Did you know? You can suggest edits to improve this peptide information.
Overview
What is PT-141?
PT-141 (Bremelanotide) is an FDA-approved synthetic peptide that acts as a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors in the central nervous system. Unlike traditional ED medications that work through vascular mechanisms, PT-141 directly influences sexual arousal pathways in the brain, making it effective for both male and female sexual dysfunction.
Key Benefits
FDA-approved route with predictable absorption, works within 45 minutes, effective for both male and female sexual dysfunction
Mechanism of Action
Activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of vascular mechanisms
Pharmacokinetics
Research Indications
Hypoactive Sexual Desire Disorder (HSDD)
FDA-approved for premenopausal women with acquired, generalized HSDD
Erectile Dysfunction
Effective in men including those unresponsive to PDE5 inhibitors
Female Sexual Arousal Disorder
Improves physiological and subjective arousal measures
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Best taken 45-60 minutes before sexual activity. Can be taken with or without food, though food may reduce nausea. Effects last 6-12 hours.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to dry
Calculate required bacteriostatic water volume using the calculator below
Draw calculated volume of bacteriostatic water into syringe
Inject water slowly down the inside wall of the vial (never directly onto powder)
Gently swirl until powder completely dissolves (never shake)
Solution should be clear - discard if cloudy or contains particles
Store reconstituted solution in refrigerator at 2-8°C
Quality Indicators
FDA-approved pharmaceutical grade
If prescribed as Vyleesi, guaranteed pharmaceutical quality and safety
White crystalline powder
Pure PT-141 appears as white to off-white lyophilized powder
Clear solution when reconstituted
Properly manufactured PT-141 dissolves completely without cloudiness
Colored or oily appearance
May indicate impurities or degradation - do not use
Compounded versions
Ensure compounding pharmacy is licensed and follows USP standards
Proper labeling with concentration
Legitimate sources provide clear concentration and purity information
What to Expect
- First 30-45 minutes: May experience mild nausea or facial flushing
- 45-90 minutes: Onset of effects - increased arousal and desire
- 2-4 hours: Peak effects - enhanced sexual response and satisfaction
- 6-12 hours: Effects gradually diminish
- Long-term: No tolerance development reported with intermittent use
Side Effects & Safety
- Common side effects: nausea (40%), flushing (20%), headache (11%)
- Take anti-nausea medication 30 minutes before if prone to nausea
- Monitor blood pressure - can cause transient decrease
- Not for use with uncontrolled hypertension or cardiovascular disease
- Avoid alcohol to minimize blood pressure effects
- FDA black box warning for blood pressure effects
References
FDA Approval Trial for Hypoactive Sexual Desire Disorder (2019)
Phase 3 trials in premenopausal women with HSDD showed statistically significant improvements in sexual desire and reduced distress related to low sexual desire.
Male Erectile Dysfunction Clinical Trial (2017)
Clinical studies demonstrated PT-141 induced erections in men with ED, including those unresponsive to PDE5 inhibitors, through central nervous system pathways.
Mechanism of Action Study (2016)
Research confirmed PT-141 selectively binds MC3R and MC4R receptors, activating neural pathways involved in sexual arousal without peripheral vasodilation.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia